Comparison of choline-PET/CT, MRI, SPECT, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a meta-analysis

Skeletal Radiology

Volumn 43, Issue 11, 2014, Pages 1503-1513

  Shen, Guohua ^a   Deng, Houfu ^a   Hu, Shuang ^a   Jia, Zhiyun ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Bone metastases; Bone scintigraphy; Meta analysis; MRI; Positron emission tomography with computed tomography; Prostate cancer; SPECT

Indexed keywords

CHOLINE; RADIOPHARMACEUTICAL AGENT;

BONE NEOPLASMS; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC USE; HUMAN; MALE; META ANALYSIS; MULTIMODAL IMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSERVER VARIATION; POSITRON EMISSION TOMOGRAPHY; PREVALENCE; PROSTATIC NEOPLASMS; REPRODUCIBILITY; SECONDARY; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STATISTICS AND NUMERICAL DATA;

BONE NEOPLASMS; CHOLINE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MULTIMODAL IMAGING; OBSERVER VARIATION; POSITRON-EMISSION TOMOGRAPHY; PREVALENCE; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84930342719     PISSN: 03642348     EISSN: 14322161     Source Type: Journal    
DOI: 10.1007/s00256-014-1903-9     Document Type: Review

References (59)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10–29.
2. 18F-choline PET in the assessment of bone metastases in prostate cancer: correlation with morphological changes on CT. Mol Imaging Biol. 2009;11:446–54.
3. Giovanella L, Castellani M, Suriano S, et al. Multi-field-of-view SPECT is superior to whole-body scanning for assessing metastatic bone disease in patients with prostate cancer. Tumori. 2011;97:629–33.
4. Zerbib M, Zelefsky MJ, Higano CS, Carroll PR. Conventional treatments of localized prostate cancer. Urology. 2008;72:S25–35.
5. Berry WR. The evolving role of chemotherapy in androgen-independent (hormone-refractory) prostate cancer. Urology. 2005;65:2–7.
6. Love C, Din AS, Tomas MB, Kalapparambath TP, Palestro CJ. Radionuclide bone imaging: an illustrative review. Radiographics. 2003;23:341–58.
7. 99mTc-based bone scan versus fluoride positron emission tomography combined with computed tomography in the assessment of bone metastases in prostate cancer patients. Imaging Decisions MRI. 2009;13:88–96.
8. Kosuda S, Kaji T, Yokoyama H, et al. Does bone SPECT actually have lower sensitivity for detecting vertebral metastasis than MRI? J Nucl Med. 1996;37:975–8.
9. Nozaki T, Yasuda K, Akashi T, Fuse H. Usefulness of single-photon emission computed tomography imaging in the detection of lumbar vertebral metastases from prostate cancer. Int J Urol. 2008;15:516–9.
10. Ghanem N, Uhl M, Brink I, et al. Diagnostic value of MRI in comparison to scintigraphy, PET, MS-CT and PET/CT for the detection of metastases of bone. Eur J Radiol. 2005;55:41–55.
11. Lecouvet FE, Geukens D, Stainier A, et al. Magnetic resonance imaging of the axial skeleton for detecting bone metastases in patients with high-risk prostate cancer: diagnostic and cost-effectiveness and comparison with current detection strategies. J Clin Oncol. 2007;25:3281–7.
12. 18 fluorine-labeled deoxyglucose. J Urol. 1996;155:994–8.
13. 11C-choline and FDG-PET in the diagnosis of biochemical prostate cancer relapse after radical treatment. Mol Imaging Biol. 2010;12:210–7.
14. Evangelista L, Guttilla A, Zattoni F, Muzzio PC, Zattoni F. Utility of choline positron emission tomography/computed tomography for lymph node involvement identification in intermediate-to high-risk prostate cancer: a systematic literature review and meta-analysis. Eur Urol. 2012;63:1040–8.
15. Berlin JA. Does blinding of readers affect the results of meta-analyses? Lancet. 1997;350:185–6.
16. Whiting P, Rutjes AW, Reitsma JB, Bossuyt PM, Kleijnen J. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol. 2003;3:25.
17. Whiting PF, Weswood ME, Rutjes AW, Reitsma JB, Bossuyt PN, Kleijnen J. Evaluation of QUADAS, a tool for the quality assessment of diagnostic accuracy studies. BMC Med Res Methodol. 2006;6:9.
18. 18 fluorodeoxyglucose positron emission tomography/computed tomography for the detection of metastases in non–small–cell lung cancer patients. Int J Cancer. 2013;132:E37–47.
19. 18F-Fluoride PET/CT. J Nucl Med. 2006;47:287–97.
20. 11C-choline PET/CT in the restaging of prostate cancer patients showing a single lesion on bone scintigraphy. Ann Nucl Med. 2010;24:485–92.
21. 99mTc bone scanning and computed tomography for single-step detection of metastases in patients with high-risk prostate cancer? Eur Urol. 2012;62:68–75.
22. 18F-Fluoromethylcholine (FCH) PET imaging in patients with castration-resistant prostate cancer: prospective comparison with standard imaging. Eur J Nucl Med Mol Imaging. 2011;38:14–22.
23. 18F-NaF PET/CT for detection of bone metastases in patients with high-risk prostate carcinoma. AJR Am J Roentgenol. 2012;199:1114–20.
24. Nozaki T, Yasuda K, Akashi T, Fuse H. Usefulness of single-photon emission computed tomography imaging in the detection of lumbar vertebral metastases from prostate cancer. Int J Urol. 2008;15:516–9.
25. 11C-choline PET/CT and bone scintigraphy in the detection of bone metastasis in patients with biochemical failure after primary treatment for prostate cancer. Eur J Nucl Med Mol Imaging. 2010;37:S269.
26. 11C-choline PET/CT detection of bone metastases in patients with PSA progression after primary treatment for prostate cancer: comparison with bone scintigraphy. Eur J Nucl Med Mol Imaging. 2012;39:13–26.
27. 18F-fluoride PET/CT compared with MRI. Eur Urol Suppl. 2012;11:e892.
28. 18F-fluoroethylcholine-PET/CT compared with bone-scan in evaluating the prostate cancer patients referring with biochemical recurrence. Eur J Nucl Med Mol Imaging. 2011;38:S138.
29. Venkitaraman R, Cook GJ, Dearnaley DP, et al. Does magnetic resonance imaging of the spine have a role in the staging of prostate cancer? Clin Oncol. 2009;21:39–42.
30. Venkitaraman R, Cook GJ, Dearnaley DP, et al. Whole-body magnetic resonance imaging in the detection of skeletal metastases in patients with prostate cancer. J Med Imaging Radiat Oncol. 2009;53:241–7.
31. Wang XY, Zhang CY, Jiang XX. Prospective study of bone metastasis from prostate cancer: comparison between large field diffusion-weighted imaging and bone scintigraphy [Chinese]. Chin J Radiol. 2009;43:131–5.
32. 18F fluoride PET-CT: a comparative study. Eur J Nucl Med Mol Imaging. 2008;35:1766–74.
33. 18F) PET/CT in the detection of prostate cancer: prospective comparison of diagnostic performance determined by masked reading. Q J Nucl Med Mol Imaging. 2011;55:448–57.
34. 18Fluorine deoxyglucose positron emission tomography, magnetic resonance imaging and bone scintigraphy for the diagnosis of bone metastases in patients with lung cancer: which one is the best?—a meta-analysis. Clin Oncol. 2011;23:350–8.
35. Beheshti M, Langsteger W, Fogelman I. Prostate cancer: role of SPECT and PET in imaging bone metastases. Semin Nucl Med. 2009;39:396–407.
36. Fogelman I, Cook G, Israel O, Van der Wall H. Positron emission tomography and bone metastases. Semin Nucl Med. 2005;35:135–42.
37. Abuzallouf S, Dayes I, Lukka H. Baseline staging of newly diagnosed prostate cancer: a summary of the literature. J Urol. 2004;171:2122–7.
38. Rigaud J, Tiguert R, Le Normand L, et al. Prognostic value of bone scan in patients with metastatic prostate cancer treated initially with androgen deprivation therapy. J Urol. 2002;168:1423–6.
39. Mankoff DA. A definition of molecular imaging. J Nucl Med. 2007;48:18N–21N.
40. Tryciecky EW, Gottschalk A, Ludema K. Oncologic imaging: interactions of nuclear medicine with CT and MRI using the bone scan as a model. Semin Nucl Med. 1997;27:142–51.
41. Gosfield 3rd E, Alavi A, Kneeland B. Comparison of radionuclide bone scans and magnetic resonance imaging in detecting spinal metastases. J Nucl Med. 1993;34:2191–8.
42. Horiuchi-Suzuki K, Konno A, Ueda M, et al. Skeletal affinity of Tc (V)-DMS is bone cell mediated and pH dependent. Eur J Nucl Med Mol Imaging. 2004;31:388–98.
43. Cook GJ, Fogelman I. The role of positron emission tomography in the management of bone metastases. Cancer. 2000;88:2927–33.
44. Savelli G, Chiti A, Grasselli G, Maccauro M, Rodari M, Bombardieri E. The role of bone SPET study in diagnosis of single vertebral metastases. Anticancer Res. 2000;20:1115–20.
45. Han L, Au-Yong T, Tong W, Chu K, Szeto L, Wong C. Comparison of bone single-photon emission tomography and planar imaging in the detection of vertebral metastases in patients with back pain. Eur J Nucl Med. 1998;25:635–8.
46. Reinartz P, Schaffeldt J, Sabri O, et al. Benign versus malignant osseous lesions in the lumbar vertebrae: differentiation by means of bone SPET. Eur J Nucl Med. 2000;27:721–6.
47. Daldrup-Link HE, Franzius C, Link TM, et al. Whole-body MR imaging for detection of bone metastases in children and young adults comparison with skeletal scintigraphy and FDG PET. Am J Roentgenol. 2001;177:229–36.
48. Vogler III JB, Murphy WA. Bone marrow imaging. Radiology. 1988;168:679–93.
49. Tombal B, Rezazadeh A, Therasse P, Van Cangh PJ, Vande Berg B, Lecouvet FE. Magnetic resonance imaging of the axial skeleton enables objective measurement of tumor response on prostate cancer bone metastases. Prostate. 2005;65:178–87.
50. Traill Z, Talbot D, Golding S, Gleeson FV. Magnetic resonance imaging versus radionuclide scintigraphy in screening for bone metastases. Clin Radiol. 1999;54:448–51.
51. Cumming J, Hacking N, Fairhurst J, Ackery D, Jenkins J. Distribution of bony metastases in prostatic carcinoma. Brit J Urol. 1990;66:411–14.
52. Lecouvet F, Simon M, Tombal B, Jamart J, Berg BV, Simoni P. Whole-body MRI (WB-MRI) versus axial skeleton MRI (AS-MRI) to detect and measure bone metastases in prostate cancer (PCa). Eur Radiol. 2010;20:2973–82.
53. Freedman GM, Negendank WG, Hudes GR, Shaer AH, Hanks GE. Preliminary results of a bone marrow magnetic resonance imaging protocol for patients with high-risk prostate cancer. Urology. 1999;54:118–23.
54. Schöder H, Herrmann K, Gönen M, et al. 2-[18F] fluoro-2-deoxyglucose positron emission tomography for the detection of disease in patients with prostate-specific antigen relapse after radical prostatectomy. Clin Cancer Res. 2005;11:4761–9.
55. Liu IJ, Zafar MB, Lai Y-H, Segall GM, Terris MK. Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organ-confined prostate cancer. Urology. 2001;57:108–11.
56. Oyama N, Akino H, Suzuki Y, et al. FDG PET for evaluating the change of glucose metabolism in prostate cancer after androgen ablation. Nucl Med Commun. 2001;22:963–9.
57. Emonds K, Swinnen J, Mortelmans L, Mottaghy F. Molecular imaging of prostate cancer. Methods. 2009;48:193–9.
58. Liu N, Ma L, Zhou W, et al. Bone metastasis in patients with non-small cell lung cancer: the diagnostic role of F-18 FDG PET/CT. Eur J Radiol. 2010;74:231–5.
59. 18FDG-PET, MRI and bone scintigraphy for diagnosis of bone metastases in patients with breast cancer. Skeletal Radiol. 2011;40:523–31.